Related Experiment Video
Updated: Jul 16, 2025

Evaluation of Left Ventricular Structure and Function using 3D Echocardiography
Published on: October 28, 2020
Optimal left ventricular ejection fraction in risk stratification of patients with cardiac sarcoidosis
Erika Hutt1, Maria Vega Brizneda2, Ghazaleh Goldar2
1Section of Cardiovascular Imaging, Heart, Vascular and Thoracic Institute, Cleveland Clinic, OH 44195, USA.
Insights
Identifying cardiac sarcoidosis patients at risk for sudden cardiac death is crucial. A left ventricular ejection fraction of 42% best predicts adverse events, with prior arrhythmia and scar being key risk factors.
Area of Science:
- Cardiology
- Cardiovascular Imaging
- Sarcoidosis Research
Background:
- Cardiac sarcoidosis (CS) poses a significant risk for sudden cardiac death (SCD).
- Accurate risk stratification is essential for managing CS patients.
- Predicting ventricular arrhythmia (VA) and mortality in CS remains a clinical challenge.
Purpose of the Study:
- To determine the optimal cutoff for left ventricular ejection fraction (LVEF) in predicting VA and all-cause mortality in CS patients.
- To identify clinical and imaging risk factors associated with adverse outcomes in CS.
Main Methods:
- Retrospective cohort study of 273 patients with established CS.
- Modified receiver operating curve analysis to find optimal LVEF cutoff.
- Cox proportional hazard regression to identify independent risk factors.
Main Results:
- Median follow-up of 7.9 years; 38% experienced the composite endpoint (VA or all-cause mortality).
- Optimal LVEF cutoff for predicting VA and mortality was 42%.
- Independent risk factors included younger age, prior VA, lower LVEF, and cardiac scar on CMR/PET.
Conclusions:
- A mildly reduced LVEF of 42% is an optimal predictor for VA and mortality in CS.
- Prior VA and evidence of cardiac scar are significant risk factors for future adverse events.
Aims:
Identifying patients with cardiac sarcoidosis (CS) who are at an increased risk of sudden cardiac death (SCD) poses a clinical challenge. We sought to identify the optimal cutoff for left ventricular ejection fraction (LVEF) in predicting ventricular arrhythmia (VA) and all-cause mortality and to identify clinical and imaging risk factors in patients with known CS.
Methods And Results:
This retrospective cohort included 273 patients with well-established CS. The primary endpoint was a composite of VA and all-cause mortality. A modified receiver operating curve analysis was utilized to identify the optimal cutoff for LVEF in predicting the primary composite endpoint. Cox proportional hazard regression analysis was used to identify independent risk factors of the outcomes. At median follow-up of 7.9 years, the rate of the primary endpoint was 38% (83 VAs and 32 all-cause deaths). The 5-year overall survival rate was 97%. The optimal cutoff LVEF for the primary composite endpoint was 42% in the entire cohort and in subjects without a history of VA. Younger age, history of VA, lower LVEF, and any presence of scar by cardiac magnetic resonance (CMR) imaging and/or positron emission tomography (PET) were found to be independent risk factors for the primary endpoint and for VA, whereas lower LVEF, baseline NT-proBNP, and any presence of scar were independent risk factor of all-cause mortality.
Conclusion:
Among patients with CS, a mild reduction in LVEF of 42% was identified as the optimal cutoff for predicting VA and all-cause mortality. Prior VA and scar by CMR or PET are strong risk factors for future VA and all-cause mortality.
More Related Videos
10:33Assessment of Right Ventricular Structure and Function in Mouse Model of Pulmonary Artery Constriction by Transthoracic Echocardiography
Published on: February 3, 2014
07:11Morphological and Functional Assessment of the Right Ventricle Using 3D Echocardiography
Published on: October 28, 2020
Related Concept Videos
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cardiomyopathy V: Interprofessional Care
Cardiomyopathy IV: Restrictive Cardiomyopathy
Cardiomyopathy I: Introduction and Classification
Cardiomyopathy II: Dilated Cardiomyopathy